Approval · Notice of Compliance 16199 · 2014
VAN-RIZATRIPTAN: Notice of Compliance 16199
Issued October 20, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16199
- Date
- October 20, 2014
- Company
- Vanc Pharmaceuticals IncRichmond, British Columbia, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Licensing agreement between two companies
- Therapeutic class
- 5-ht1 receptor agonist
- Canadian reference product
- MAXALT (Merck Frosst Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VAN-RIZATRIPTAN | 02428512 | Cancelled Post Market |
| VAN-RIZATRIPTAN | 02428520 | Cancelled Post Market |
Medicinal ingredients
- RIZATRIPTAN BENZOATE 5 MG per TAB
- RIZATRIPTAN BENZOATE 10 MG per TAB